Korean trials. If results prove Oviplex 97% better than the traditional CA125 ovarian cancer diagnostic blood tests then HTX is in. Results expected out around June 2011.
HTX Price at posting:
5.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
